Boyle Scott N

Chief Business OfficerC4 Therapeutics, Inc. (CCCC) · full profile →Form 4 · filed Feb 18, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 14, 2026Tax withholding(F)7K$1.89$14K299K
Feb 14, 2026Option exercise(M)21K$0306K
Feb 13, 2026Grant(A)200K$0308K
Feb 13, 2026Option exercise(M)5K$0308K
Feb 13, 2026Tax withholding(F)2K$1.89$3K306K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000180) within minutes of acceptance. Every field above traces to the original document. Verify it directly: